- Erasca Announces $45 Million Oversubscribed Private Placement Financing
- Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
- Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
- Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
- Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
- Erasca Reports Third Quarter 2023 Financial Results and Business Updates
- Erasca to Present at Upcoming Investor Conferences in November
- Erasca to Present at the Cantor Global Healthcare Conference
More ▼
Key statistics
On Thursday, Erasca Inc (ERAS:NSQ) closed at 2.15, 42.38% above the 52 week low of 1.51 set on Dec 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.11 |
---|---|
High | 2.17 |
Low | 2.03 |
Bid | 2.10 |
Offer | 2.19 |
Previous close | 2.09 |
Average volume | 472.33k |
---|---|
Shares outstanding | 173.34m |
Free float | 138.09m |
P/E (TTM) | -- |
Market cap | 362.28m USD |
EPS (TTM) | -0.8327 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼